Skip to Content

Join the 'Infliximab' group to help and get support from people like you.

Infliximab News

FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade

Posted 27 Apr 2017 by Drugs.com

INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade®i (infliximab), across all eligible indications. In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. Renflexis is the first Samsung Bioepis product approved for marketing in the United States (US). “Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achievin ... Read more

Related support groups: Rheumatoid Arthritis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Renflexis

Early Treatment Equals Better Results for Rheumatoid Arthritis

Posted 25 Apr 2017 by Drugs.com

TUESDAY, April 25, 2017 – Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found. The findings stem from an analysis of more than 600 patients who were initially diagnosed with rheumatoid arthritis (RA) between 1990 and 1994. They were tracked for over 20 years. Over the study time frame, investigators assessed key symptoms of RA, such as swollen and/or tender joints, and indications of disability. All deaths were also noted. The research team found that patients who started treatment for RA within the first half-year after the first symptoms surfaced tended to have no greater levels of disability over a 20-year period than patients who required no treatment. ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Sulfasalazine, Orencia, Rituximab, Leflunomide, Azathioprine, Juvenile Rheumatoid Arthritis, Arava, Xeljanz, Juvenile Idiopathic Arthritis, Infliximab

New Meds Make Inroads Against Crohn's Disease

Posted 13 Apr 2017 by Drugs.com

THURSDAY, April 13, 2017 – Fewer Americans with Crohn's disease are ending up in the hospital than in the past, according to a new federal study. Crohn's is a chronic inflammatory bowel disorder that often leads to surgery for most with the disease. Hospitalization rates for Crohn's disease remained stable in the United States between 2003 and 2013. That's a change from a study done from 1998 to 2004 that saw more than 4 percent increases in Crohn's hospitalizations each year, researchers with the U.S. Centers for Disease Control and Prevention said. The stable hospital rates are likely due to the 1998 introduction of a new class of biologic drugs. Examples of these medications used to treat Crohn's disease include: adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia) and ustekinumab (Stelara), according to the U.S. National Institute of Diabetes and Digestive and Kidney ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Ulcerative Colitis, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Stelara, Ulcerative Colitis - Active, Crohn's Disease - Acute, Cimzia, Ulcerative Colitis - Maintenance, Infliximab, Adalimumab, Inflectra, Amjevita, Certolizumab, Ustekinumab

Could a Germ Link Gum Disease, Rheumatoid Arthritis?

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – A specific germ may help explain the long-noticed connection between gum disease and rheumatoid arthritis, a new study suggests. The discovery might also point to the potential origins of the painful joint illness. "If we're right, this will totally change the view of rheumatoid arthritis and treatment of patients," said study co-author Dr. Felipe Andrade. But, Andrade, an associate professor of medicine at the Johns Hopkins University School of Medicine in Baltimore, cautioned that this is "an early finding that needs confirmation by others." Rheumatoid arthritis is a chronic form of arthritis linked to an overactive immune system. It can affect a variety of body systems, not just the joints. The disease affects roughly 1.5 million U.S. adults, according to the U.S. Centers for Disease Control and Prevention. For more than a century, scientists have noticed ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Oral and Dental Conditions, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Gingivitis, Otezla, Imuran, Sulfasalazine, Orencia, Rituximab, Leflunomide, Azathioprine, Juvenile Rheumatoid Arthritis, Arava, Xeljanz

Inflectra Approved as 'Biosimilar' to Remicade

Posted 7 Apr 2016 by Drugs.com

WEDNESDAY, April 6, 2016 – The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses. In a media release, the agency said Inflectra was biosimilar to Janssen Biotech's Remicade (infliximab), first licensed in 1998. A biosimilar drug is sanctioned based on its maker's ability to show that it is "highly similar" to an already-approved biological drug that is generally derived from a living organism, such as a person, animal, microorganism or yeast, the FDA said. The maker of a biosimilar drug also must prove that the product has no "clinically meaningful difference" in safety and effectiveness from the original drug, and that the newer product has only "minor differences in clinically inactive components" from the original. Inflectra's most ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Maintenance, Plaque Psoriasis, Ulcerative Colitis - Active, Crohn's Disease - Acute, Ulcerative Colitis - Maintenance, Infliximab, Inflectra

FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade

Posted 7 Apr 2016 by Drugs.com

April 5, 2016 – The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab), which was originally licensed in 1998. Inflectra is approved and can be prescribed by a health care professional for the treatment of: adult patients and pediatric patients (ages six years and older) with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy; adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy; patients with moderately to severely active rheumatoid arthritis in combination with methotrexate; patients with active ankylosing spondylitis (arthritis of ... Read more

Related support groups: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Remicade, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Infliximab, Inflectra

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead researcher Dr. Sebastien Viatte, a research fellow at the University of Manchester in England. Using data from several sources on thousands of patients in the United Kingdom, researchers found that gene mutations at a location on a chromosome called HLA-DRBl were associated with rheumatoid arthritis severity and the response to treatment with tumor necrosis factor (TNF) inhibitor drugs. This study, Viatte said, is a potentially important first step toward personalized medicine for patients with the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Orencia, Rituximab, Simponi, Leflunomide, Cimzia, Juvenile Rheumatoid Arthritis, Azathioprine, Arava, Xeljanz, Infliximab

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by Drugs.com

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – which include drugs such as adalimumab (Humira), anakinra (Kineret) and etanercept (Enbrel) – have allowed patients to gain better control of rheumatoid arthritis when taken early in the course of disease, the researchers explained. But some of the new drugs top $20,000 annually, according to the April 21 online report in the journal Arthritis & Rheumatology. "Many patients face a growing and unacceptable financial burden for access to treatment," said study lead author Dr. Jinoos Yazdany of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Orencia, Rituximab, Leflunomide, Azathioprine, Arava, Xeljanz, Infliximab, Adalimumab, Kineret, Etanercept

Smokers May Get Less Benefit From Drugs for Arthritic Back Pain

Posted 10 Feb 2015 by Drugs.com

TUESDAY, Feb. 10, 2015 – Smoking may hamper the effects of certain drugs used to treat inflammatory arthritis in the lower back, a new study from Switzerland says. Researchers from University Hospital Zurich looked at how 700 people with this type of arthritis responded to treatment with a class of drugs called tumor necrosis factor (TNF) inhibitors. About two-thirds of the patients were smokers. After one to two years of treatment, the drugs were significantly less effective in smokers. The difference was particularly apparent among patients who had higher levels of an inflammatory marker called C-reactive protein at the start of the study. Former smokers did not experience reduced effectiveness from the drugs, according to the study. The research only saw an association between smoking and the drugs' benefits, not a cause-and-effect relationship. The results were published online ... Read more

Related support groups: Back Pain, Rheumatoid Arthritis, Smoking, Humira, Enbrel, Remicade, Simponi, Cimzia, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Certain Autoimmune Drugs in Pregnancy May Up Newborn Infection Risk: Study

Posted 3 Oct 2014 by Drugs.com

FRIDAY, Oct. 3, 2014 – When given to pregnant women, a common treatment for ulcerative colitis may inadvertently lower their baby's ability to fight off infections at birth, new French research suggests. The treatment, called anti-TNF therapy, is an injected, artificial antibody. This type of medication is widely seen as a safe and effective way to tackle a wide range of autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel conditions that include ulcerative colitis and Crohn's disease. It's not unusual for pregnant women to receive the treatment, given that inflammatory bowel diseases often strike women of childbearing age. However, this type of drug can cross the placenta and reach the fetus, the study authors said. And four French cases – all involving babies born to women exposed to Remicade (infliximab) during pregnancy – suggest the therapy may cause newborn ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Crohn's Disease, Enbrel, Remicade, Ulcerative Colitis, Inflammatory Bowel Disease, Simponi, Cimzia, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Popular Crohn's, Colitis Drugs Not Linked to Short-Term Cancer Risk: Study

Posted 18 Jun 2014 by Drugs.com

WEDNESDAY, June 18, 2014 – A popular class of drugs used to treat inflammatory bowel disease isn't linked to an increase in the short-term risk of cancer, Danish researchers report. Researchers found that people with Crohn's disease or colitis who received the drugs – tumor necrosis factor alpha (TNF-a) antagonists – had about the same risk of cancer as other people with these inflammatory bowel diseases who were not treated with the medication. The drugs work by interrupting the function of TNF-a, a substance used by the immune system to increase inflammation. "Treatment with these drugs inhibits the inflammatory response in the gastrointestinal tract thereby leading to reduced symptoms," said lead author Dr. Nynne Nyboe Andersen of the Statens Serum Institute in Copenhagen. The problem is that TNF-a also serves a key role in protecting the body against cancer, raising concerns that ... Read more

Related support groups: Humira, Crohn's Disease, Enbrel, Remicade, Ulcerative Colitis, Colorectal Cancer, Inflammatory Bowel Disease, Simponi, Cimzia, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Certain Rheumatoid Arthritis Drugs May Also Protect Patients' Hearts, Studies Find

Posted 27 Oct 2013 by Drugs.com

SATURDAY, Oct. 26 – Drugs that people with rheumatoid arthritis use to help ease the symptoms of the disease might also help ward off heart trouble, two new studies find. Researchers in Sweden found that so-called "biologic" drugs, known as tumor necrosis factor inhibitors, or anti-TNFs, slightly reduce the risk for acute coronary syndrome – a condition that includes angina and heart attack in which blood supply to the heart muscle is suddenly blocked. In another study, British scientists also found taking these drugs was associated with a lower risk for heart attack in patients with rheumatoid arthritis. The findings were to be presented Saturday at the American College of Rheumatology's annual meeting in San Diego. Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal. The roughly 1.3 million Americans affected by the ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Remicade, Simponi, Cimzia, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Expensive or Not, Rheumatoid Arthritis Drugs Have Similar Effect: Study

Posted 1 Jul 2013 by Drugs.com

MONDAY, July 1 – Treatment with a pricey biological drug was no better than cheaper, conventional therapy in terms of reducing time off from work for people with rheumatoid arthritis, a new study finds. Swedish researchers assessed lost work days among rheumatoid arthritis patients who had not responded to initial treatment with a standard medication, methotrexate. The group of 204 patients were randomly given either the biological drug infliximab (Remicade) or conventional combination therapy with the non-biologics sulfasalazine plus hydroxychloroquine. At the start of the study, the average amount of lost work time was 17 days per month for all patients. During the 21-month study, the patients receiving conventional therapy lost about six fewer days of work per month, compared with about five fewer days for those taking Remicade – not a significant difference. Regardless of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Remicade, Plaquenil, Hydroxychloroquine, Sulfasalazine, Infliximab, Azulfidine, Sulfazine, Trexall, Methotrexate LPF Sodium, Plaquenil Sulfate, Folex PFS, Quineprox, Rheumatrex Dose Pack, Azulfidine EN-tabs

Rheumatoid Arthritis Treatment May Not Work As Well for Heavier Patients

Posted 18 Jun 2013 by Drugs.com

TUESDAY, June 18 – Overweight and obese people with rheumatoid arthritis are less likely to go into remission in the early stages of the disease and require much more drug treatment than people with normal weight, according to a new study. The study included nearly 350 people with early rheumatoid arthritis (RA) who underwent a treatment meant to achieve remission of their disease. The strategy included strict follow-up visits, as well as treatment with steroids and the drug methotrexate, combined with anti-tumor necrosis factor (anti-TNF) therapy if a good response didn't occur. Anti-TNF drugs are used to reduce inflammation in a variety of conditions. At six and 12 months of follow-up, overweight and obese patients had lower rates of remission. After 12 months, a higher percentage of overweight and obese patients were still on anti-TNF therapy, compared to normal-weight patients. The ... Read more

Related support groups: Obesity, Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Simponi, Cimzia, Infliximab, Adalimumab, Etanercept, Golimumab, Trexall, Certolizumab, Methotrexate LPF Sodium, Folex PFS, Rheumatrex Dose Pack

Many Stop Taking Rheumatoid Arthritis Meds Too Soon: Study

Posted 14 Jun 2013 by Drugs.com

FRIDAY, June 14 – About half of rheumatoid arthritis patients stopped taking their medications within two years after they started them, a new study finds. Rheumatoid arthritis affects about one in 100 people worldwide and can cause progressive joint destruction, deformity, pain and stiffness. The disease can reduce physical function, quality of life and life expectancy. The main reason about one-third of patients discontinued their medications was because the drugs lost their effectiveness, the study authors found. Other reasons included safety concerns (20 percent), doctor preference (nearly 28 percent), patient preference (about 18 percent) and access to treatment (9 percent), according to the study results, which were presented Thursday at the annual meeting of the European League Against Rheumatism (EULAR), in Madrid, Spain. Rheumatoid arthritis "is a progressive disease, which, ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Remicade, Simponi, Cimzia, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Ulcerative Colitis, Ankylosing Spondylitis, Crohn's Disease - Acute, Behcet's Disease, Celiac Disease, Rheumatoid Arthritis, Crohn's Disease, Bullous Pemphigoid, Psoriatic Arthritis, view more... Crohn's Disease - Maintenance, Sjogren's Syndrome, Inflammatory Bowel Disease, Pulmonary Fibrosis, Uveitis, Neurosarcoidosis, Spondyloarthritis, Psoriasis, SAPHO Syndrome, Toxic Epidermal Necrolysis, Subcorneal Pustular Dermatosis, Sarcoidosis, Pemphigus, Juvenile Idiopathic Arthritis, Giant Cell Arteritis, Cogan's Syndrome, Kawasaki Disease, Pemphigoid, Polychondritis, Plaque Psoriasis, Pyoderma Gangrenosum

Related Drug Support Groups

Remicade, Inflectra, Renflexis

Infliximab Patient Information at Drugs.com